References
- Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-ofevidence-1 studies. Breast Cancer Res 2014; 16: 428.
- Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.
- Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
- Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013; 49: 1825-35.
- Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
- Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.
- Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
- Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, et al. Riskgroup discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 1999; 80: 419-26.
- Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.
- Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-5.
- Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208.
- Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16: 3129-36.
- Peyrat JP, Vanlemmens L, Fournier J, Huet G, Révillion F, Bonneterre J. Prognostic value of p53 and urokinase-type plasminogen activator in nodenegative human breast cancers. Clin Cancer Res 1998; 4: 189-96.
- Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998; 4: 177-82.
- Malmström P, Bendahl PO, Boiesen P, Brünner N, Idvall I, Fernö M. S-phase fraction and urokinase plasminogen activator are better markers for dist ant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001; 19: 2010-9.
- Meo S, Dittadi R, Peloso L, Gion M. The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer. Int J Biol Markers 2004; 19: 282-8.
- De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, et al. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res 2009; 29: 1475-82.
- Rabi ZA, Todorović-Raković N, Vujasinović T, Milovanović J, Nikolić-Vukosavljević D. Markers of progression and invasion in short term follow up of untreated breast cancer patients. Cancer Biomark 2015; 15: 745-54.
- Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, et al. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 2001; 7: 2448-57.
- Berney CR, Yang J, Fisher RJ, Russell PJ, Crowe PJ. Correlates of urokinasetype plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol Res 1998; 10: 47-54.
- Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-9.
- Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, et al. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 1998; 18: 2187-97.
- Bouchet C, Ferrero-Poüs M, Hacène K, Becette V, Spyratos F. Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma. Int J Biol Markers 2003; 18: 207-17.
- Buta M, Džodić R, Đurišić I, Marković I, Vujasinović T, Markićević M, et al. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up. Tumour Biol 2015; 36: 8193-200.
- Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022-8.
- Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005; 7: R256-66.
- Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsin B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-64.
- Cufer T, Borstnar S, Vrhovec I. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 2003; 18: 106-15.